Pituitary tumor transforming gene (PTTG) carboxy-terminal...

Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C435S975000, C530S300000, C530S350000, C530S324000

Reexamination Certificate

active

06858586

ABSTRACT:
Disclosed is a method of inhibiting neoplastic cellular proliferation and/or transformation of mammalian cells, including cells of human origin, in vitro or in vivo. The inventive method involves the use of a composition containing a pituitary tumor transforming gene carboxy-terminal peptide (PTTG-C), which can be comprised in a chimeric protein, which has the ability to regulate endogenous pituitary tumor transforming gene (PTTG) expression and/or function in a dominant negative manner. Kits comprising the inventive compositions are also disclosed for the treatment of neoplastic cellular proliferation in vitro or in vivo. Isolated PTTG-C peptides and PTTG-C-containing chimeric proteins are described.

REFERENCES:
patent: WO 9009442 (1990-08-01), None
patent: WO 9822587 (1998-05-01), None
PCT International Search Report—PCT/US 97/21463, Nov. 22, 1997.
Marra, M., et al., “The WashC-HHMI Mouse EST project, AC W81747”, EMBL Database, Jun. 27, 1996, Heidelberg, XP002066845.
Hillier, L., et al., The WashU-Merck EST project, AC AA007646, EMBL Database, Jul. 28, 1996, Heidelberg, XP002066846.
Holton, T., et al., “ACQ57612”, EMBL Database, Sep. 5, 1994, Heidelberg, XP002066847.
Nippon Telegraph and Telephone Corp.: “ACQ75553”, EMBL Database, Aug. 4, 1995, Heidelberg, XP002066848.
Gonsky, R., et al., “Transforming DNA Sequences Present in Human Prolactin-Secreting Pituitary Tumors”, Molec. Endocrin., 5(11): 1687-1695, Nov. 1991.
Pei, L., et al., “Isolation and Characterization of a Pituitary Tumor-Transforming Gene (PTTG)”, Molec. Endocrin., 11(4): 433-441, Apr. 1997.
Shimon, I., et al., “Genetic Basis of Endocrine Disease”, J. Clin. Endocrin. And Metab., 82(6): 1675-1681, Jun. 1997.
Chen. L., et al., “Identification of the human pituitary tumor transforming gene (hPTTG) family: molecular structure, expression, and chromosomal localization.”, 1: Gene May 2, 2000; 248 (102): 41-50. Abstract Only.
Heaney, A.P., “Expression of pituitary-tumor transforming gene in colorectal tumours”, 1: Lancet Feb. 26, 2000; 355(9205): 716-9.
Heaney, A.P. “Early Involvement of Estrogen-induced pituitary tumor transforming gene and fibroblast growth factor expression in prolactinoma pathogenesis”, 1: Nat Med Nov., 1999; 5(11): 1317-21.
Suhardja, A.S., et al., “Molecular pathogenesis of pituitary adenomas: a review.”, Acta Neurochir (Wien) 1999; 141(7): 729-36. Abstract Only.
Ren, R., et al., “Identification of a ten-amino acid proline-rich SH3 binding site.”, Science Feb 19, 1993; 259(5098): 1157-61. Abstract Only.
Liu, X., et al., “The v-Src SH3 domain binds phosphatidylinositol 3′-kinase.”, Mol Cell Biol Sep. 1993; 13(9): 5225-32. Abstract Only.
Gout, I., et al., “The GTPase dynamin binds to and is activated by a subset of SH3 domains.” Cel Oct. 8, 1993; 75(1): 25-36.
Yu, H., et al., “Solution structure of the SH3 domain of Src and identification of its ligan-binding site.” Science Dec. 4, 1992: 258(5088): 1665-8. Abstract Only.
Lee. I.A., et al., “Cloning and expression of human cDNA encoding human homologue of pituitary tumor transforming gene.”, Biochem Mol. Biol Int May 1999; 47(5): 891-7. Abstract Only.
Zou, H., et al., “Identification of a vertebrate sister-chromatid separation inhibitor involved in transformation and tumorigenesis.”, Science Jul. 16, 1999; 285(5426): 418-22. Abstract Only.
Zhang, X., et al., “Pituitary tumor transforming gene (PTTG) expression in pituitary adenomas.” J Clin Endocrinol Metab Feb. 1999; 84(2): 761-7.
Prezant, T.R., et al., “An intronless homolog of human proto-oncogene hPTTG is expressed in pituitary tumors; evidence for hPTTG family.”, J Clin Endocrinol Metab Mar. 1999; 84(3): 1149-52.
Fujimoto, N., et al., “Establishment of an estrogen responsive rat pituitary cell sub-line MtTE-2.” Endocr J Jun. 1999; 46(3): 389-96. Abstract Only.
Ramos-Morales, F., et al., “Cell cycle regulated expression and phosphorylation of hpttg proto-oncogene product.”, Oncogene Jan. 20, 2000; 19(3): 403-9. Abstract Only.
McCabe C.J., et al., “PTTG—a new pituitary tumour transforming gene.”, J Endocrinol Aug. 1999; 162(2): 163-6. Abstract Only.
Kakar, S.S., “Molecular cloning, genomic organization. and identification of the promoter for the human pituitary tumor transforming gene (PTTG).”, Gene Nov. 29, 1999; 240(2): 317-24. Abstract Only.
Dominguez, A., et al., “hpttg, a human homologue of rat pttg, is overexpressed in hematopoietic neoplasms. Evidence for a transcriptional activation function of hPTTG.”, Oncogene Oct. 29, 1998; 17(17): 2187-93. Abstract Only.
Pei, L., “Pituitary tumor-transforming gene protein associates with ribosomal protein S10 and a novel human homologue of DnaJ in testicular cells.”, J Biol Chem Jan. 29, 1999; 274(5): 3151-8.
Saez, C., et al., “hpttg is over-expressed in pituitary adenomas and other primary epithelial neoplasias.”, Oncogene Sep. 23, 1999; 18(39): 5473-6. Abstract Only.
Pei, L., “Genomic Organization and identification of an enhancer element containing binding sites for multiple proteins in rat pituitary tumor-transforming gene.”, J Biol Chem Feb. 27, 1998; 273(9): 5219-25.
Wang, Z., et al., “Characterization of the murine pituitary tumor transforming gene (PTTG) and its promoter.”, Endocrinology Feb. 2000; 141(2): 763-71.
Zhang, X., et al., “Structure, expression and function of human pituitary tumor-transforming gene (PTTG).”, Mol Endocrinol Jan. 1999; 13(1): 156-66.
Heaney, Anthony, P., et al., “Pituitary tumor transforming gene: a novel factor in pituitary tumour formation,” Balliere's Clinical Endocrinology and Metabolism, vol. 13, No. 3, pp. 367-380, 1999.
Deonarain; Ligand-targeted receptor-mediated vectors for gene delivery, 1998, Exp. Opin. Ther. Patents 8(1):53-69.
Eck et al.; Gene-Based Therapy, 1996, The Pharmacological Basis of Therapeutics:77-101.
Accession No. AAT21011, 1996.
Accession No. H66067, 1995.

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Pituitary tumor transforming gene (PTTG) carboxy-terminal... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Pituitary tumor transforming gene (PTTG) carboxy-terminal..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pituitary tumor transforming gene (PTTG) carboxy-terminal... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-3509232

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.